# Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer

> **NCT00025467** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Endometrial Adenoacanthoma
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Cell Carcinoma
- Endometrial Clear Cell Carcinoma
- Endometrial Papillary Serous Carcinoma
- Recurrent Endometrial Carcinoma

## Interventions

- **DRUG:** thalidomide
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00025467
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025467, "Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00025467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*